NEW YORK (GenomeWeb) – Israeli cancer diagnostics developer NovellusDx has raised $10 million in a private financing round.

The round, led by life sciences holding company IntraCure and life sciences venture capital financier Pontifax, includes an option for an additional $10 million investment, the company said in a statement.

Founded in 2012, the firm has developed technology to monitor signaling pathways and identify driver mutations in different kinds of cancer, and monitor the effects of targeted therapies on those mutations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.